Despite initial success using markers like CD133 to isolate, study and target CICs across many cancer types, including colorectal carcinoma (CRC), conflicting reports suggest that CD133 and other current markers are insufficient to reliably purify CICs4,8. This evidence concerns the gene PROM1 and colorectal carcinoma.